Barclays’s Apollo Endosurgery, Inc. APEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-7,047
Closed -$69.9K 5334
2023
Q1
$69.9K Sell
7,047
-10,715
-60% -$106K ﹤0.01% 4339
2022
Q4
$177K Buy
17,762
+16,604
+1,434% +$124K ﹤0.01% 3905
2022
Q3
$6K Buy
+1,158
New +$6.42K ﹤0.01% 4487
2021
Q4
Sell
-6,772
Closed -$61K 4888
2021
Q3
$61K Buy
6,772
+5,373
+384% +$46.2K ﹤0.01% 4069
2021
Q2
$11K Buy
1,399
+900
+180% +$6.17K ﹤0.01% 4618
2021
Q1
$3K Buy
+499
New +$2.47K ﹤0.01% 4543
2019
Q4
Sell
-146
Closed 6981
2019
Q3
$0 Buy
+146
New +$463 ﹤0.01% 7278
2019
Q2
Sell
-353
Closed -$1K 7410
2019
Q1
$1K Buy
+353
New +$1.24K ﹤0.01% 6945

Barclays's APEN Position: Q2 2023 in Review

Barclays sold out of Apollo Endosurgery, Inc. (APEN) in Q2 2023, closing a stake of 7,047 shares — an estimated $69.9K sold.

Barclays first reported a position in APEN in Q1 2019 and held it in 8 quarters. The position peaked at $177K in Q4 2022. 0 funds tracked by Wall St. Rank hold APEN as of Q2 2023.

  • Barclays reported no remaining Apollo Endosurgery, Inc. position as of Q2 2023 after selling out during the quarter.
  • Barclays sold 7,047 Apollo Endosurgery, Inc. shares in Q2 2023, an estimated $69.9K.
  • Barclays first reported a position in Apollo Endosurgery, Inc. in Q1 2019 and held it in 8 quarters.
  • Barclays's Apollo Endosurgery, Inc. position peaked at $177K in Q4 2022.
  • 0 funds tracked by Wall St. Rank held Apollo Endosurgery, Inc. as of Q2 2023.

Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.